Glycogen phosphorylase inhibition improves beta cell function. (18th June 2017)

• Record Type: Journal Article
• Authors: Nagy, Lilla; Márton, Judit; Vida, András; Kis, Gréta; Bokor, Éva; Kun, Sándor; Gönczi, Mónika; Docsa, Tibor; Tóth, Attila; Antal, Miklós; Gergely, Pál; Csóka, Balázs; Pacher, Pal; Somsák, László; Bai, Péter
• Is Part Of: British journal of pharmacology. Volume 175:Number 2(2018)
• Page Start: 301
• Page End: 319
• Publication Date: 2017-06-18
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.13819
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Glycogen phosphorylase (GP) is the key enzyme for glycogen degradation. GP inhibitors (GPi‐s) are glucose lowering agents that cause the accumulation of glucose in the liver as glycogen. Glycogen metabolism has implications in beta cell function. Glycogen degradation can maintain cellular glucose levels, which feeds into catabolism to maintain insulin secretion, and elevated glycogen degradation levels contribute to glucotoxicity. The purpose of this study was to assess whether influencing glycogen metabolism in beta cells by GPi‐s affects the function of these cells. Experimental Approach: The effects of structurally different GPi‐s were investigated on MIN6 insulinoma cells and in a mouse model of diabetes. Key Results: GPi treatment increased glycogen content and, consequently, the surface area of glycogen in MIN6 cells. Furthermore, GPi treatment induced insulin receptor β (InsRβ), Akt and p70S6K phosphorylation, as well as pancreatic and duodenal homeobox 1(PDX1) and insulin expression. In line with these findings, GPi‐s enhanced non‐stimulated and glucose‐stimulated insulin secretion in MIN6 cells. The InsRβ was shown to co‐localize with glycogen particles as confirmed by in silico screening, where components of InsR signalling were identified as glycogen‐bound proteins. GPi‐s also activated the pathway of insulin secretion, indicated by enhanced glycolysis, mitochondrial oxidation and calcium signalling. Finally, GPi‐s increased the size of islets of Langerhans and improved glucose‐induced insulin release in mice. Conclusion and Implications: These data suggest that GPi‐s also target beta cells and can be repurposed as agents to preserve beta cell function or even ameliorate beta cell dysfunction in different forms of diabetes. Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visithttp://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc